MT-0169 is a fusion protein commercialized by Molecular Templates, with a leading Phase I program in Natural Killer Cell Lymphomas. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of MT-0169’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for MT-0169 is expected to reach an annual total of $57 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
MT-0169 is under development for the treatment of relapsed or refractory multiple myeloma and relapsed/refractory non-Hodgkin lymphomas including Mantle cell lymphoma (MCL), nodal MCL; Diffuse large B-cell lymphoma (DLBCL), DLBCL-NOS, Plasmablastic lymphoma (PbL), Primary effusion lymphoma (PEL), Primary effusion lymphoma (PMBL); follicular lymphoma, burkitt lymphoma (BL); Peripheral T-cell lymphoma (PTCL), PTCL-NOS, Angioimmunoblastic T-cell lymphoma (AITL), Extranodal NK/T-cell lymphoma (ENKTL)-nasal type. The therapeutic candidate acts by targeting cells expressing CD38. It is a second generation engineered toxin body (ETB) comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein. The therapeutic candidate is developed based on Engineered Toxin Bodies (ETB) platform technology. It is a new molecular entity. It is administered through intravenous route.
Molecular Templates Overview
Molecular Templates (MTI), formerly Threshold Pharmaceuticals, is a clinical-stage oncology company. The company discovers and develops biologic therapeutics for cancer. It’s pipeline products include MT-5111, SLAMF-7, CTLA-4, MT-0169 and MT-6402. MTI lead product MT-3724, a fusion protein, is designed for the treatment of Non-Hodgkin Lymphoma; and MT-0169 is used for the treatment of multiple myeloma. The company also develops Engineered Toxin Bodies (ETBs) for the treatment of breast cancer, melanoma and allogeneic stem cell transplantation. It develops ETBs for various targets including CD20, CD38, HER2, and PD-L1. MTI is headquartered in Austin, Texas, the US.
The company reported revenues of (US Dollars) US$38.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$18.8 million in FY2020. The operating loss of the company was US$80.1 million in FY2021, compared to an operating loss of US$102.1 million in FY2020. The net loss of the company was US$83 million in FY2021, compared to a net loss of US$104.9 million in FY2020. The company reported revenues of US$4.2 million for the third quarter ended September 2022, a decrease of 4% over the previous quarter.
For a complete picture of MT-0169’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.